Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study
Our findings underscore the heterogeneity and aggressive nature of PACC. Despite the improved prognosis for patients with resectable/borderline-resectable disease, OS remains poor, particularly for those with locally advanced or metastatic disease. The identification of actionable molecular targets in a significant proportion of patients highlights the potential for personalized therapeutic approaches. Future research should focus on tailored treatment strategies to exploit these molecular vulnerabilities, which may offer new options for improving outcomes in this rare malignancy.
Authors
- Claire Yee (ORCID: https://orcid.org/0000-0003-1601-9163)
- Bobak Seddighzadeh
- Jason S. Starr (ORCID: https://orcid.org/0000-0003-4922-1392)
- Cody R. Eslinger (ORCID: https://orcid.org/0000-0002-8057-0841)
- Rish K. Pai (ORCID: https://orcid.org/0000-0002-2692-221X)
- Mohamad Bassam Sonbol (ORCID: https://orcid.org/0000-0002-6931-242X)
- Christopher Hartley (ORCID: https://orcid.org/0000-0002-2237-3102)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Zaid Elsabbagh (ORCID: https://orcid.org/0009-0008-5501-9282)
- Þorvarður R. Hálfdánarson (ORCID: https://orcid.org/0000-0001-8460-1257)
Institutions
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1200/po-24-00450
- Citations
- 4
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18